45 Participants Needed

Exercise Training for Pulmonary Arterial Hypertension

CF
YR
Overseen ByYogesh Reddy
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Mayo Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that participants should not have started a new pulmonary vasodilator in the last 60 days.

What data supports the effectiveness of the treatment Aerobic Training, Aerobic Exercise, Cardiovascular Exercise, Physical Activity Therapy, Leg Training for Pulmonary Arterial Hypertension?

Research shows that specialized exercise programs can improve symptoms, exercise capacity, and quality of life in patients with pulmonary arterial hypertension. These programs have been found to be safe and beneficial when added to medical treatment, although the best methods and duration are still being studied.12345

Is exercise training safe for people with pulmonary arterial hypertension?

Exercise training for people with pulmonary arterial hypertension has been shown to have an acceptable safety profile in several studies, with benefits like improved symptoms and quality of life. However, it's important that these programs are conducted by experienced centers to ensure safety.13678

How does exercise training differ from other treatments for pulmonary arterial hypertension?

Exercise training for pulmonary arterial hypertension is unique because it is a non-drug therapy that focuses on improving physical fitness and quality of life through aerobic and leg exercises. Unlike traditional drug treatments, it helps enhance muscle function and cardiorespiratory fitness, offering a complementary approach to medical therapy.13679

What is the purpose of this trial?

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

Research Team

YR

Yogesh Reddy, M.B.B.S

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults with Pulmonary Arterial Hypertension (PAH) who are stable, not hospitalized recently, and haven't started new PAH drugs in the last 60 days. Healthy individuals without heart failure can also join as controls. Exclusions include recent severe cardiovascular events, inability to exercise, need for oxygen supplementation, pregnancy or potential pregnancy without effective contraception.

Inclusion Criteria

Criterion Summary: For patients with Pulmonary Arterial Hypertension (PAH): - You have given consent to participate in the trial. - You are in NYHA Class II-IV. - Your Left Ventricular Ejection Fraction (LVEF) is equal to or greater than 40% in the past year. - You have not been hospitalized due to heart failure in the last 30 days. - You have not started a new pulmonary vasodilator in the last 60 days. - Your mean Pulmonary Arterial (PA) pressure is equal to or greater than 20 mmHg with Pulmonary Vascular Resistance (PVR) greater than 2 Wood units, as determined by right heart catheterization. - Your exercise Pulmonary Capillary Wedge Pressure (PCWP) is less than 25 mm Hg. - You are symptomatic with PAH and planning to undergo exercise right heart catheterization for reassessment of exertional symptoms. For healthy controls: - You have given consent to participate in the trial. - You do not have a known diagnosis of heart failure.

Exclusion Criteria

You have experienced a heart attack, stroke, or heart-related hospitalization in the last 30 days, or you have certain heart conditions that could cause difficulty in breathing or exercising. You are unable to walk without assistance, have chronic low oxygen levels, have certain muscle or bone conditions, or have been involved in certain medical trials recently. You are pregnant, breastfeeding, or planning to become pregnant, or you have a severe psychiatric disorder, have had recent suicidal behavior, or are suspected of drug abuse.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants complete baseline study assessments before randomization

1 week

Treatment

Participants undergo either aerobic training or leg training for 12 weeks

12 weeks

Follow-up

Participants are monitored for changes in skeletal muscle O2 diffusive conductance and quality of life

4 weeks

Treatment Details

Interventions

  • Aerobic Training
  • Leg Training
Trial Overview The study compares two types of physical training: whole body aerobic exercises versus targeted leg strength training. It aims to determine which method better improves symptoms and life quality in PAH patients.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Leg TrainingExperimental Treatment1 Intervention
Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo leg training for 12 weeks, and then repeat study assessments.
Group II: Aerobic TrainingActive Control1 Intervention
Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo aerobic training for 12 weeks, and then repeat study assessments.
Group III: Healthy ControlsActive Control1 Intervention
Healthy controls will be enrolled to complete the baseline study assessments for generation of normal reference values for comparison. Healthy controls will not undergo randomized exercise training interventions or repeat assessments.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

In a study of 18 women with pulmonary arterial hypertension (PAH) undergoing 10 weeks of vigorous aerobic exercise training, significant improvements were observed in cardiac function, including a decrease in systemic vascular resistance at peak exercise, suggesting enhanced heart efficiency.
The study found that vigorous aerobic exercise did not lead to declines in left ventricular function, indicating that such training may be safe and beneficial for women with PAH by potentially reducing afterload and preserving diastolic function.
Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension.Woolstenhulme, JG., Guccione, AA., Herrick, JE., et al.[2023]
In a study of 25 females with pulmonary hypertension undergoing a 10-week aerobic exercise training program, significant improvements in cardiorespiratory function were observed in those with high (HI) and low (LI) increases in 6-minute walk test distance, but not in those with negative (NEG) adaptations.
The HI group showed notable enhancements in ventilatory efficiency and other key respiratory metrics post-training, suggesting that some patients may struggle with exercise adaptation due to sustained ventilatory inefficiency, which could limit their exercise capacity.
Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance.Morris, ZV., Chin, LMK., Chan, L., et al.[2023]
A specialized exercise training and rehabilitation program is recommended as an effective add-on treatment for patients with pulmonary arterial hypertension, showing significant improvements in symptoms, exercise capacity, and quality of life across over 470 patients in various studies.
The safety profile of these exercise programs is acceptable, with some studies indicating excellent survival rates over 1 to 2 years, although most studies had small sample sizes and were not designed to measure long-term clinical outcomes.
Principles of rehabilitation and reactivation: pulmonary hypertension.Marra, AM., Egenlauf, B., Bossone, E., et al.[2015]

References

Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension. [2023]
Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance. [2023]
Principles of rehabilitation and reactivation: pulmonary hypertension. [2015]
4.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study. [2022]
Exercise training in patients with pulmonary arterial hypertension: a case report. [2021]
Skeletal muscle dysfunctions in pulmonary arterial hypertension: Effects of aerobic exercise training. [2023]
A Review of Exercise Interventions in Pulmonary Arterial Hypertension and Recommendations for Rehabilitation Programing. [2020]
Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class. [2020]
Pulmonary hypertension and exercise training: a synopsis on the more recent evidences. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security